Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of “On-Target, Off-Tumor Toxicity”

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

(2021) Yael C. Cohen et al.   NATURE MEDICINE

Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment

(2021) Rongqun Guo et al.   Biomarker Research

CAR T-cell therapy in multiple myeloma: more room for improvement

(2021) Phaik Ju Teoh et al.   Blood Cancer Journal

Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers

(2021) Yu J. Cao et al.   ACS Synthetic Biology

Integrated analysis of multimodal single-cell data

(2021) Yuhan Hao et al.   CELL

Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs

(2021) Nadia Anikeeva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

(2021) Nicholas A. Vitanza et al.   NATURE MEDICINE

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

(2021) Heng Mei et al.   Journal of Hematology & Oncology

Deciphering human macrophage development at single-cell resolution

(2020) Zhilei Bian et al.   NATURE

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

Recent advances in CAR-T cell engineering

(2020) Ruihao Huang et al.   Journal of Hematology & Oncology

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

(2020) Tobias Roider et al.   NATURE CELL BIOLOGY

Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis

(2020) Arun C. Habermann et al.   Science Advances

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

(2020) Matteo Libero Baroni et al.   Journal for ImmunoTherapy of Cancer

A rational mouse model to detect on-target, off-tumor CAR T cell toxicity

(2020) Mauro Castellarin et al.   JCI Insight

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

(2020) Kevin R. Parker et al.   CELL

CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?

(2020) Joseph E. Maakaron et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma

(2020) Yunfan Sun et al.   CELL

Single-Nucleus and In Situ RNA–Sequencing Reveal Cell Topographies in the Human Pancreas

(2020) Luca Tosti et al.   GASTROENTEROLOGY

CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

(2019) Robbie G. Majzner et al.   CLINICAL CANCER RESEARCH

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

(2019) Clara Bueno et al.   LEUKEMIA

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity

(2019) Peter van Galen et al.   CELL

Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia

(2019) Diego Sánchez-Martínez et al.   BLOOD

Anti-CD1a CAR T cells to selectively target T-ALL

(2019) Paul M. Maciocia et al.   BLOOD

Rapid Relapse of Large B‐Cell Lymphoma after CD19 Directed CAR‐T‐Cell Therapy due to CD‐19 Antigen Loss

(2019) Ali Bukhari et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

(2019) Katherine D. Cummins et al.   HAEMATOLOGICA

A human liver cell atlas reveals heterogeneity and epithelial progenitors

(2019) Nadim Aizarani et al.   NATURE

Guiding T lymphopoiesis from pluripotent stem cells by defined transcription factors

(2019) Rongqun Guo et al.   CELL RESEARCH

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

(2018) Miriam Y. Kim et al.   CELL

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

(2018) Yao Wang et al.   OncoImmunology

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

(2017) Esther Drent et al.   MOLECULAR THERAPY

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

(2017) Alec J. Walker et al.   MOLECULAR THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Driving better and safer HER2-specific CARs for cancer therapy

(2017) Xianqiang Liu et al.   Oncotarget

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

(2017) Kaichao Feng et al.   Protein & Cell

Superior Therapeutic Index in Lymphoma Therapy: CD30 + CD34 + Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack

(2016) Andreas A Hombach et al.   MOLECULAR THERAPY

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

(2015) Xin Huang et al.   PLoS One

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells

(2014) Keisuke Watanabe et al.   JOURNAL OF IMMUNOLOGY

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

(2013) Eric Tran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY